|Bid||9.80 x 0|
|Ask||10.25 x 0|
|Day's range||9.60 - 10.70|
|52-week range||6.91 - 32.29|
|Beta (5Y monthly)||0.20|
|PE ratio (TTM)||N/A|
|Earnings date||30 May 2019 - 03 Jun 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.00|
It is doubtless a positive to see that the ImmuPharma plc (LON:IMM) share price has gained some 50% in the last three...
British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trail, and Avion will commercialise the drug exclusively in the United States, ImmuPharma said.
Dimitri Dimitriou is the CEO of ImmuPharma plc (LON:IMM). This report will, first, examine the CEO compensation levels...
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dimitri Dimitriou is the CEO of ImmuPharma plc (LON:IMM). This report will, first, examine...